Alimera Sciences Inc
NASDAQ:ALIM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Liandi Clean Technology Inc
OTC:LNDT
|
US |
Alimera Sciences Inc
Research & Development
Alimera Sciences Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alimera Sciences Inc
NASDAQ:ALIM
|
Research & Development
-$17.4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-7%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$15B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Alimera Sciences Inc
Glance View
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. The company is headquartered in Alpharetta, Georgia and currently employs 145 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. The firm focuses on diseases affecting the retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant that treats patients by delivering a continuous microdose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. The Company’s product ILUVIEN is also used for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. Its ILUVIEN is also used in the European Economic Area (EEA) to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The firm commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.
See Also
What is Alimera Sciences Inc's Research & Development?
Research & Development
-17.4m
USD
Based on the financial report for Jun 30, 2024, Alimera Sciences Inc's Research & Development amounts to -17.4m USD.
What is Alimera Sciences Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-7%
Over the last year, the Research & Development growth was -6%. The average annual Research & Development growth rates for Alimera Sciences Inc have been -14% over the past three years , -9% over the past five years , and -7% over the past ten years .
